BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 30021904)

  • 1. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
    Wood CD; Carvell T; Gunnell A; Ojeniyi OO; Osborne C; West MJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes.
    Su C; Lu F; Soldan SS; Lamontagne RJ; Tang HY; Napoletani G; Farrell PJ; Tempera I; Kossenkov AV; Lieberman PM
    PLoS Pathog; 2021 Aug; 17(8):e1009834. PubMed ID: 34352044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr Virus Nuclear Antigen 3 (EBNA3) Proteins Regulate EBNA2 Binding to Distinct RBPJ Genomic Sites.
    Wang A; Welch R; Zhao B; Ta T; Keleş S; Johannsen E
    J Virol; 2015 Dec; 90(6):2906-19. PubMed ID: 26719268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300.
    Wang C; Zhou H; Xue Y; Liang J; Narita Y; Gerdt C; Zheng AY; Jiang R; Trudeau S; Peng CW; Gewurz BE; Zhao B
    J Virol; 2018 May; 92(9):. PubMed ID: 29467311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth.
    Zhao B; Zou J; Wang H; Johannsen E; Peng CW; Quackenbush J; Mar JC; Morton CC; Freedman ML; Blacklow SC; Aster JC; Bernstein BE; Kieff E
    Proc Natl Acad Sci U S A; 2011 Sep; 108(36):14902-7. PubMed ID: 21746931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
    Rowe M; Raithatha S; Shannon-Lowe C
    J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
    Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes.
    Schmidt SC; Jiang S; Zhou H; Willox B; Holthaus AM; Kharchenko PV; Johannsen EC; Kieff E; Zhao B
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):554-9. PubMed ID: 25540416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice.
    Bristol JA; Nelson SE; Ohashi M; Casco A; Hayes M; Ranheim EA; Pawelski AS; Singh DR; Hodson DJ; Johannsen EC; Kenney SC
    PLoS Pathog; 2024 Apr; 20(4):e1012132. PubMed ID: 38620028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
    Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
    Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus-encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma.
    Leopizzi M; Mundo L; Messina E; Campolo F; Lazzi S; Angeloni A; Marchese C; Leoncini L; Giordano C; Slack F; Trivedi P; Anastasiadou E
    Blood; 2024 Feb; 143(5):429-443. PubMed ID: 37847858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EBV nuclear antigen EBNALP dismisses transcription repressors NCoR and RBPJ from enhancers and EBNA2 increases NCoR-deficient RBPJ DNA binding.
    Portal D; Zhao B; Calderwood MA; Sommermann T; Johannsen E; Kieff E
    Proc Natl Acad Sci U S A; 2011 May; 108(19):7808-13. PubMed ID: 21518914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nuclear chaperone nucleophosmin escorts an Epstein-Barr Virus nuclear antigen to establish transcriptional cascades for latent infection in human B cells.
    Liu CD; Chen YL; Min YL; Zhao B; Cheng CP; Kang MS; Chiu SJ; Kieff E; Peng CW
    PLoS Pathog; 2012; 8(12):e1003084. PubMed ID: 23271972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells.
    Beer S; Wange LE; Zhang X; Kuklik-Roos C; Enard W; Hammerschmidt W; Scialdone A; Kempkes B
    Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2200512119. PubMed ID: 35857872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway.
    Pegman PM; Smith SM; D'Souza BN; Loughran ST; Maier S; Kempkes B; Cahill PA; Simmons MJ; Gélinas C; Walls D
    J Virol; 2006 Aug; 80(16):8133-44. PubMed ID: 16873269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression.
    Wang L; Toomey NL; Diaz LA; Walker G; Ramos JC; Barber GN; Ning S
    J Virol; 2011 Aug; 85(16):8328-37. PubMed ID: 21680528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus.
    Pich D; Mrozek-Gorska P; Bouvet M; Sugimoto A; Akidil E; Grundhoff A; Hamperl S; Ling PD; Hammerschmidt W
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.
    Schlee M; Krug T; Gires O; Zeidler R; Hammerschmidt W; Mailhammer R; Laux G; Sauer G; Lovric J; Bornkamm GW
    J Virol; 2004 Apr; 78(8):3941-52. PubMed ID: 15047810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RUNX super-enhancer control through the Notch pathway by Epstein-Barr virus transcription factors regulates B cell growth.
    Gunnell A; Webb HM; Wood CD; McClellan MJ; Wichaidit B; Kempkes B; Jenner RG; Osborne C; Farrell PJ; West MJ
    Nucleic Acids Res; 2016 Jun; 44(10):4636-50. PubMed ID: 26883634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NP9 protein encoded by the human endogenous retrovirus HERV-K(HML-2) negatively regulates gene activation of the Epstein-Barr virus nuclear antigen 2 (EBNA2).
    Gross H; Barth S; Pfuhl T; Willnecker V; Spurk A; Gurtsevitch V; Sauter M; Hu B; Noessner E; Mueller-Lantzsch N; Kremmer E; Grässer FA
    Int J Cancer; 2011 Sep; 129(5):1105-15. PubMed ID: 21710493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.